{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:09:14Z","timestamp":1785848954039,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","award":["2122-HQ-000067"],"award-info":[{"award-number":["2122-HQ-000067"]}],"id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","award":["2122-HQ-000067"],"award-info":[{"award-number":["2122-HQ-000067"]}],"id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunocompromised patients are predisposed to severe COVID-19. Here we compare homotypic and heterotypic humoral and cellular immune responses to Omicron BA.1 in organ transplant patients across a diverse clinical spectrum. We perform variant-specific pseudovirus neutralization assays for D614G, and Omicron-BA.1, -BA.2, and Delta variants. We also measure poly-and monofunctional T-cell responses to BA.1 and ancestral SARS-CoV-2 peptide pools. We identify that partially or fully-vaccinated transplant recipients after infection with Omicron BA.1 have the greatest BA.1 neutralizing antibody and BA.1-specific polyfunctional CD4<jats:sup>+<\/jats:sup>and CD8<jats:sup>+<\/jats:sup>T-cell responses, with potent cross-neutralization against BA.2. In these patients, the magnitude of the BA.1-directed response is comparable to immunocompetent triple-vaccinated controls. A subset of patients with pre-Omicron infection have heterotypic responses to BA.1 and BA.2, whereas uninfected transplant patients with three doses of vaccine demonstrate the weakest comparative responses. These results have implications for risk of infection, re-infection, and disease severity among immune compromised hosts with Omicron infection.<\/jats:p>","DOI":"10.1038\/s41467-022-32235-x","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T10:03:24Z","timestamp":1659607404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings"],"prefix":"10.1038","volume":"13","author":[{"given":"Victor H.","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6833-6625","authenticated-orcid":false,"given":"Javier T.","family":"Solera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Queenie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria G.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2880-3780","authenticated-orcid":false,"given":"Berta G.","family":"Arbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Rod Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Marinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9638-873X","authenticated-orcid":false,"given":"Matthew","family":"Ierullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avneet Kaur","family":"Virk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kurtesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faranak","family":"Mavandadnejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Majchrzak-Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vathany","family":"Kulasingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6090-4437","authenticated-orcid":false,"given":"Anne-Claude","family":"Gingras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1961-0477","authenticated-orcid":false,"given":"Deepali","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1751-7159","authenticated-orcid":false,"given":"Atul","family":"Humar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"32235_CR1","doi-asserted-by":"crossref","unstructured":"Goldman, J. D., Robinson, P. C., Uldrick, T. S. & Ljungman, P. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J. Immunother. Cancer. 9, e002630 (2021).","DOI":"10.1136\/jitc-2021-002630"},{"key":"32235_CR2","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1097\/TP.0000000000003860","volume":"105","author":"T Marinelli","year":"2021","unstructured":"Marinelli, T. et al. Prospective clinical, virologic, and immunologic assessment of COVID-19 in transplant recipients. Transplantation 105, 2175\u201383 (2021).","journal-title":"Transplantation"},{"key":"32235_CR3","doi-asserted-by":"crossref","first-page":"e13637","DOI":"10.1111\/tid.13637","volume":"23","author":"MR Pereira","year":"2021","unstructured":"Pereira, M. R. et al. Outcomes of COVID-19 in solid organ transplant recipients: a matched cohort study. Transpl. Infect. Dis. 23, e13637 (2021).","journal-title":"Transpl. Infect. Dis."},{"key":"32235_CR4","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1056\/NEJMc2111462","volume":"385","author":"VG Hall","year":"2021","unstructured":"Hall, V. G. et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N. Engl. J. Med. 385, 1244\u20131246 (2021).","journal-title":"N. Engl. J. Med"},{"key":"32235_CR5","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.7326\/L21-0282","volume":"174","author":"WA Werbel","year":"2021","unstructured":"Werbel, W. A. et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann. Intern. Med. 174, 1330\u20131332 (2021).","journal-title":"Ann. Intern. Med"},{"key":"32235_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMsb2104756","volume":"385","author":"L Corey","year":"2021","unstructured":"Corey, L. et al. SARS-CoV-2 variants in patients with immunosuppression. N. Engl. J. Med. 385, 562\u2013566 (2021).","journal-title":"N. Engl. J. Med"},{"key":"32235_CR7","doi-asserted-by":"crossref","unstructured":"Kumar, D. et al. Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine. Am. J. Transplant. (2022).","DOI":"10.1111\/ajt.17020"},{"key":"32235_CR8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.7326\/M21-3480","volume":"175","author":"D Kumar","year":"2022","unstructured":"Kumar, D. et al. Neutralization of SARS-CoV-2 variants in transplant recipients after two and three doses of mRNA-1273 vaccine: secondary analysis of a randomized trial. Ann. Intern. Med. 175, 226\u201333 (2022).","journal-title":"Ann. Intern. Med."},{"key":"32235_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67172-6","volume":"10","author":"AG L\u2019Huillier","year":"2020","unstructured":"L\u2019Huillier, A. G. et al. T-cell responses following natural influenza infection or vaccination in solid organ transplant recipients. Sci. Rep. 10, 10104 (2020).","journal-title":"Sci. Rep."},{"key":"32235_CR10","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1097\/01.TP.0000438024.10375.2d","volume":"97","author":"M Cowan","year":"2014","unstructured":"Cowan, M. et al. Impact of immunosuppression on recall immune responses to influenza vaccination in stable renal transplant recipients. Transplantation 97, 846\u2013853 (2014).","journal-title":"Transplantation"},{"key":"32235_CR11","doi-asserted-by":"crossref","unstructured":"Cassaniti, I. et al. Characterization of Varicella-Zoster (VZV) specific T cell response in healthy subjects and transplanted patients by using enzyme linked immunospot (ELISpot) assays. Vaccines 9, 875 (2021).","DOI":"10.3390\/vaccines9080875"},{"key":"32235_CR12","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1111\/ajt.16534","volume":"21","author":"C Hirzel","year":"2021","unstructured":"Hirzel, C. et al. Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients. Am. J. Transplant. 21, 2246\u20132253 (2021).","journal-title":"Am. J. Transplant."},{"key":"32235_CR13","doi-asserted-by":"publisher","first-page":"104938","DOI":"10.1016\/j.antiviral.2020.104938","volume":"183","author":"C Rondaan","year":"2020","unstructured":"Rondaan, C. et al. Immune response to varicella-zoster virus before and after renal transplantation. Antivir. Res. 183, 104938 (2020).","journal-title":"Antivir. Res."},{"key":"32235_CR14","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1093\/infdis\/jiab542","volume":"224","author":"VH Ferreira","year":"2021","unstructured":"Ferreira, V. H. et al. Severe acute respiratory syndrome coronavirus 2 infection induces greater T-cell responses compared to vaccination in solid organ transplant recipients. J. Infect. Dis. 224, 1849\u20131860 (2021).","journal-title":"J. Infect. Dis."},{"key":"32235_CR15","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1111\/ajt.16766","volume":"21","author":"VG Hall","year":"2021","unstructured":"Hall, V. G. et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. Am. J. Transplant. 21, 3980\u20133989 (2021).","journal-title":"Am. J. Transplant."},{"key":"32235_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMc2119641","volume":"386","author":"F Schmidt","year":"2022","unstructured":"Schmidt, F. et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N. Engl. J. Med. 386, 599\u2013601 (2022).","journal-title":"N. Engl. J. Med"},{"key":"32235_CR17","doi-asserted-by":"crossref","unstructured":"Yu, J. et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants. N. Engl. J. Med. 386, 1579\u20131580 (2022).","DOI":"10.1056\/NEJMc2201849"},{"key":"32235_CR18","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","volume":"603","author":"R Keeton","year":"2022","unstructured":"Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 603, 488\u2013492 (2022).","journal-title":"Nature"},{"key":"32235_CR19","unstructured":"SARS-CoV-2 Whole Genome Sequencing in Ontario. https:\/\/www.publichealthontario.ca\/-\/media\/Documents\/nCoV\/epi\/covid-19-sars-cov2-whole-genome-sequencing-epi-summary.pdf?sc_lang=en (2022)."},{"key":"32235_CR20","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3389\/fimmu.2018.00276","volume":"9","author":"E Panagioti","year":"2018","unstructured":"Panagioti, E., Klenerman, P., Lee, L. N., van der Burg, S. H. & Arens, R. Features of effective T cell-inducing vaccines against chronic viral infections. Front. Immunol. 9, 276 (2018).","journal-title":"Front. Immunol."},{"key":"32235_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"RA Seder","year":"2008","unstructured":"Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247\u2013258 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"32235_CR22","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"32235_CR23","doi-asserted-by":"publisher","first-page":"eabl6141","DOI":"10.1126\/scitranslmed.abl6141","volume":"14","author":"X Charmetant","year":"2022","unstructured":"Charmetant, X. et al. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients. Sci. Transl. Med. 14, eabl6141 (2022).","journal-title":"Sci. Transl. Med."},{"key":"32235_CR24","unstructured":"Kwon, J. H. et al. mRNA vaccine effectiveness against COVID-19 hospitalization among solid organ transplant recipients. J. Infect. Dis. (2022)."},{"key":"32235_CR25","doi-asserted-by":"crossref","unstructured":"Karaba, A. H. et al. A fourth dose of COVID-19 vaccine does not induce neutralization of the Omicron variant among solid organ transplant recipients with suboptimal vaccine response. Transplantation. 106, 1440\u20131444 (2022).","DOI":"10.1097\/TP.0000000000004140"},{"key":"32235_CR26","doi-asserted-by":"crossref","unstructured":"Davidov, Y. et al. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients. J. Hepatol. S0168-8278, 00237-9 (2022).","DOI":"10.1016\/S0168-8278(22)01880-3"},{"key":"32235_CR27","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1111\/ajt.16503","volume":"21","author":"C Hirzel","year":"2021","unstructured":"Hirzel, C. et al. Natural influenza infection produces a greater diversity of humoral responses than vaccination in immunosuppressed transplant recipients. Am. J. Transplant. 21, 2709\u20132718 (2021).","journal-title":"Am. J. Transplant."},{"key":"32235_CR28","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1056\/NEJMc2031670","volume":"383","author":"T Aydillo","year":"2020","unstructured":"Aydillo, T. et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N. Engl. J. Med. 383, 2586\u20132588 (2020).","journal-title":"N. Engl. J. Med."},{"key":"32235_CR29","doi-asserted-by":"crossref","unstructured":"Meiring, S. et al. Prolonged shedding of SARS-CoV-2 at high viral loads amongst hospitalised immunocompromised persons living with HIV, South Africa. Clin. Infect. Dis. (2022).","DOI":"10.1016\/j.ijid.2021.12.060"},{"key":"32235_CR30","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","volume":"23","author":"P Moss","year":"2022","unstructured":"Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23, 186\u2013193 (2022).","journal-title":"Nat. Immunol."},{"key":"32235_CR31","doi-asserted-by":"crossref","unstructured":"Abe, K. T. et al. A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight. 5, e142362 (2020).","DOI":"10.1172\/jci.insight.142362"},{"key":"32235_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21653-y","volume":"12","author":"MM Aynaud","year":"2021","unstructured":"Aynaud, M. M. et al. A multiplexed, next generation sequencing platform for high-throughput detection of SARS-CoV-2. Nat. Commun. 12, 1405 (2021).","journal-title":"Nat. Commun."},{"key":"32235_CR33","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1080\/22221751.2020.1835448","volume":"9","author":"B Meyer","year":"2020","unstructured":"Meyer, B. et al. Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT). Emerg. Microbes Infect. 9, 2394\u20132403 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"32235_CR34","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41590-021-01126-6","volume":"23","author":"VG Hall","year":"2022","unstructured":"Hall, V. G. et al. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat. Immunol. 23, 380\u2013385 (2022).","journal-title":"Nat. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32235-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32235-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32235-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T09:03:07Z","timestamp":1700902987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32235-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32235"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32235-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"assertion":[{"value":"21 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.K. has received research grant from Roche, GSK, and advisory fees from Roche, GSK, Sanofi, Merck and Exevir. A.H. has received research grants from Roche and Merck and advisory fees from Merck and Takeda. A.C.G. has received research funds from a research contract with Providence Therapeutics Holdings, Inc for other projects. No other authors have competing interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4489"}}